The incidence of eye disease is growing as the world's population ages and suffers increasingly from conditions such as diabetes. Pfizer is building on its expertise in treating diseases of the eye, including glaucoma and retinal diseases, such as age-related macular degeneration (AMD) and diabetic macular edema (DME), to expand its portfolio of ophthalmic compounds and improve the treatment options available to patients worldwide.
Conditions
Age-related Macular Degeneration (AMD)
Damage to the retina, usually in adults over 55, leading to vision loss.
Diabetic Macular Edema
Thickening of the retina due to the abnormal accumulation of fluid in the retina, causing visual blurring; may progress to vision loss if untreated.
Glaucoma
A group of disorders that, if untreated, may lead to damage to the optic nerve. Damage to the optic nerve may lead to vision loss, and may progress to blindness. Most people with glaucoma have elevated fluid pressure in the eye, a condition known as increased intraocular pressure.